Keywords
ALK partners
non-small cell lung cancer
Categories
How to Cite
Abstract
Lung cancer carcinogenesis is increasingly related to genetic disorders that lead to the use of specific targeted therapies which improve clinical outcome and survival. Gene fusion is one of the mechanisms of lung cancer pathogenesis besides gene mutation. The oncogenic echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion gene was the first described in non-small cell lung cancer (NSCLC) and it’s the most frequent ALK rearrangement which occurs in approximately 5% of NSCLC. The development of sequencing technology has allowed the discovery of other ALK partners that cause an ALK fusion in NSCLC. They are still less known, however. The aim of this review is to report the novel ALK fusions in NSCLC described in the literature and their particular characteristics. We will present the kinesin family member 5B (KIF5B) - ALK fusion, the huntingtin interacting protein 1 (HIP 1)- ALK fusion, and other uncommon ALK fusions.
References
Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007 Aug 2;448(7153):561-6. https://doi.org/10.1038/nature05945
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014 Dec 4; 371(23):2167-77. https://doi.org/10.1056/nejmoa1408440
Takeuchi K, Choi YL, Togashi Y, Soda M, Hatano S, Inamura K, et al. KIF5B, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res. 2009 May 1; 15(9):3143-9. https://doi.org/10.1158/1078-0432.ccr-08-3248
Wong D, Leung E, Wong S, Tin VP, Sihoe AD, Cheng LC, et al. A Novel KIF5B-ALK variant in nonsmall cell lung cancer. Cancer. 2011 Jun 15;117(12):2709-18. https://doi.org/10.1002/cncr.25843
Kimura H, Nakajima T, Takeuchi K, Soda M, Mano H, Lizasa T, et al. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity. Lung Cancer. 2012 Jan;75(1):66-72. https://doi.org/10.1016/j.lungcan.2011.05.027
Wang R, Pan Y, Li C, Hu H, Zhang Y, Li H, et al. The use of quantitative real-time reverse transcriptase PCR for 5' and 3' portions of ALK transcripts to detect ALK rearrangements in lung cancers. Clin Cancer Res. 2012 Sep 1;18(17): 4725-32. https://doi.org/10.1158/1078-0432.ccr-12-0677
Wang Q, Yang X, He Y, Ma Q, Lin L, Fu P, et al. droplet digital PCR for absolute quantification of EML4-ALK gene rearrangement in lung adenocarcinoma. J Mol Diagn. 2015 Sep; 17(5):515-20. https://doi.org/10.1016/j.jmoldx.2015.04.002
Kwak El, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010 Oct 28;363(18): 1693-703. https://doi.org/10.1056/nejmoa1006448
Hong M, Kim RN, Song JY, Choi SJ, Oh E, Lira ME, et al. HIP 1-ALK, a novel fusion protein identified in lung adenocarcinoma. J Thorac Oncol. 2014 Mar;9(3):419-22. https://doi.org/10.1097/jto.0000000000000061
Fang D, Zhang B, Gu Q, Lira M, Xu Q, Sun H, et al. HIP 1-ALK, a novel alk fusion variant that responds to crizotinib. J Thorac Oncol. 2014 Mar;9(3) :285-94. https://doi.org/10.1097/jto.0000000000000087
Ou SI, Klempner SJ, Greenbowe JR, Azada M, Schrock AB, Ali SM, et al. Identification of a novel HIP 1-ALK fusion variant in non-small-cell lung cancer and discovery of ALK I1171 mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib. J Thorac Oncol. 2014 Dec ;9(12):1821-5. https://doi.org/10.1097/jto.0000000000000368
Togashi Y, Soda M, Sakata S, Sugawara E, Hatano S, Asaka R, et al. KLC1-ALK :a novel fusion in lung cancer identified using a formalin fixed paraffin embedded tissue only. Plos One. 2012;7(2):e31323. https://doi.org/10.1371/journal.pone.0031323
Choi YL, Lira ME, Hong M, Kim RN, Choi SJ, Song JY, et al. A novel fusion of TPR and ALK in lung adenocarcinoma. J Thoracic Oncol. 2014 Apr;9(4):563-6. https://doi.org/10.1097/jto.0000000000000093
Shan L, Jiang P, Xu F, Zhang W, Guo L, Wu J, et al. BIRC6-ALK, a novel fusion gene in ALK break-apart FISH-negative lung adenocarcinoma, responds to crizotinib. J Thorac Oncol. 2015 Jun; 10(6):e37-9. https://doi.org/10.1097/jto.0000000000000467
Kim RN, Choi YL, Lee MS, Lira ME, Mao M, Mann D, et al. SEC31A-ALK fusion gene in lung adenocarcinoma. Cancer Res Treat. 2016 Jan ;48(1):398-402. https://doi.org/10.4143/crt.2014.254
Gu FF, Zhang Y, Liu YY, Hong XH, Liang JY, Tong F, et al. Lung adenocarcinoma harboring concomittant SPTBN1-ALK fusion, c-Met overexpression and HER-2 amplification with inherent resistance to crizotinib chemotherapy and radiotherapy. J Hematol Oncol. 2016 Aug 5;9(1):66. https://doi.org/10.1186/s13045-016-0296-8
Rivoka K, Guo A, Zeng Q, Possemato A, Yu J, hack H, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007 Dec 14;131(6):1190-203. https://doi.org/10.1016/j.cell.2007.11.025
Jung Y, Kim P, Jung Y, Keum J, Kim SN, Choi YS, et al. Discovery of ALK-PTPN3 gene fusion from human non-small-cell lung carcinoma cell line using next generation RNA sequencing. Genes Chromosomes Cancer. 2012 Jun;51(6):590-7. https://doi.org/10.1002/gcc.21945
Ou SH, Bartlett CH, Mino-Kinudson M, Cui J, Lafrate AJ. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer :a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist. 2012;17(11):1351-75. https://doi.org/10.1634/theoncologist.2012-0311
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2019 Hind El Yacoubi et al.
